• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分子动力学模拟揭示了类固醇对雄激素受体突变的可能激动/拮抗机制。

Molecular dynamics simulations reveal the plausible agonism/antagonism mechanism by steroids on androgen receptor mutations.

作者信息

Kocak Abdulkadir, Yildiz Muslum

机构信息

Department of Chemistry, Gebze Technical University, 41400, Kocaeli, Turkey.

Department of Molecular Biology and Genetics, Gebze Technical University, 41400, Kocaeli, Turkey.

出版信息

J Mol Graph Model. 2022 Mar;111:108081. doi: 10.1016/j.jmgm.2021.108081. Epub 2021 Nov 19.

DOI:10.1016/j.jmgm.2021.108081
PMID:34826715
Abstract

Androgen receptors (AR) are the primary drug target in prostate cancer (PCa). There are several drugs developed against its activity for prostate cancer treatment, but cancer cells revive AR signaling against those drugs by using alternative steroids such as glucocorticoids. In addition, antagonists become agonists due to emergence of mutations in AR gene. The mechanism by which antagonists are converted into agonists and how AR signaling is recovered by other steroids has yet to be fully elucidated. In this study, we interrogated the role of bicalutamide conformation in its antagonist function and how glucocorticoids such as prednisolone and dexamethasone revive AR signaling at the molecular level by means of molecular dynamics. We found that the ''closed'' conformation of bicalutamide is essential for its antagonist function and W741 residue is forcing it into this conformation. Moreover, we show that prednisolone and dexamethasone behave like natural agonist DHT which confirm the experimental results that show their role in the reviving AR signaling in the case of AR mutation.

摘要

雄激素受体(AR)是前列腺癌(PCa)的主要药物靶点。已经开发了几种针对其活性用于前列腺癌治疗的药物,但癌细胞通过使用诸如糖皮质激素等替代类固醇来恢复针对这些药物的AR信号传导。此外,由于AR基因中出现突变,拮抗剂会变成激动剂。拮抗剂如何转化为激动剂以及其他类固醇如何恢复AR信号传导的机制尚未完全阐明。在本研究中,我们通过分子动力学研究了比卡鲁胺构象在其拮抗剂功能中的作用,以及泼尼松龙和地塞米松等糖皮质激素如何在分子水平上恢复AR信号传导。我们发现比卡鲁胺的“封闭”构象对其拮抗剂功能至关重要,并且W741残基将其强制成这种构象。此外,我们表明泼尼松龙和地塞米松的行为类似于天然激动剂双氢睾酮(DHT),这证实了实验结果,即显示它们在AR突变情况下恢复AR信号传导中的作用。

相似文献

1
Molecular dynamics simulations reveal the plausible agonism/antagonism mechanism by steroids on androgen receptor mutations.分子动力学模拟揭示了类固醇对雄激素受体突变的可能激动/拮抗机制。
J Mol Graph Model. 2022 Mar;111:108081. doi: 10.1016/j.jmgm.2021.108081. Epub 2021 Nov 19.
2
Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.利用分子动力学模拟和自由能计算研究氨基酸突变诱导R-比卡鲁胺从雄激素受体拮抗剂转变为激动剂的分子机制。
J Comput Aided Mol Des. 2016 Dec;30(12):1189-1200. doi: 10.1007/s10822-016-9992-2. Epub 2016 Nov 15.
3
Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.使用分子动力学模拟探索R-比卡鲁胺/S-1与野生型/ W741L雄激素受体的相互作用机制
Mol Biosyst. 2015 Dec;11(12):3347-54. doi: 10.1039/c5mb00499c. Epub 2015 Oct 7.
4
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.一种糖皮质激素反应性突变雄激素受体表现出独特的配体特异性:对雄激素非依赖性前列腺癌的治疗意义。
Endocrinology. 2002 May;143(5):1889-900. doi: 10.1210/endo.143.5.8778.
5
Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.从雌激素受体拮抗剂中学习:基于结构的新型抗雄激素药物的鉴定,对多种临床相关雄激素受体突变体有效。
Chem Biol Drug Des. 2012 Mar;79(3):300-12. doi: 10.1111/j.1747-0285.2011.01290.x. Epub 2012 Jan 11.
6
Conformational dynamics of androgen receptors bound to agonists and antagonists.与激动剂和拮抗剂结合的雄激素受体的构象动力学。
Sci Rep. 2021 Aug 5;11(1):15887. doi: 10.1038/s41598-021-94707-2.
7
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.雄激素受体的新型突变:比卡鲁胺撤药综合征的一种可能机制。
Cancer Res. 2003 Jan 1;63(1):149-53.
8
Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.雄激素受体表达及比卡鲁胺拮抗雄激素受体抑制雌激素受体阴性乳腺癌中的β-连环蛋白转录复合物
Cell Physiol Biochem. 2017;43(6):2212-2225. doi: 10.1159/000484300. Epub 2017 Oct 25.
9
In silico studies on the molecular interactions of steroid hormones and steroid hormone mimicking drugs in the androgen receptor binding cleft - Implications for prostate cancer treatment.雄激素受体结合裂隙中甾体激素和类甾体激素药物分子相互作用的计算研究-对前列腺癌治疗的启示。
Steroids. 2024 Aug;208:109456. doi: 10.1016/j.steroids.2024.109456. Epub 2024 Jun 16.
10
Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations.通过分子动力学模拟研究雄激素受体中无激动活性和拮抗活性的分子基础。
J Mol Graph Model. 2008 Nov;27(4):452-8. doi: 10.1016/j.jmgm.2008.08.001. Epub 2008 Aug 9.

引用本文的文献

1
Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance.前列腺癌中的雄激素受体动态变化:从疾病进展到治疗抵抗
Front Oncol. 2025 Feb 11;15:1542811. doi: 10.3389/fonc.2025.1542811. eCollection 2025.
2
DeepAR: a novel deep learning-based hybrid framework for the interpretable prediction of androgen receptor antagonists.DeepAR:一种基于深度学习的新型混合框架,用于雄激素受体拮抗剂的可解释预测。
J Cheminform. 2023 May 6;15(1):50. doi: 10.1186/s13321-023-00721-z.
3
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
雄激素受体配体结合域的部分开放构象与耐药突变。
Acta Crystallogr F Struct Biol Commun. 2023 Apr 1;79(Pt 4):95-104. doi: 10.1107/S2053230X23002224. Epub 2023 Mar 30.